• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.

作者信息

Eichenauer D A, Kreissl S, Bühnen I, Baues C, Kobe C, van Heek L, Goergen H, Fuchs M, Hartmann S, von Tresckow B, Engert A, Borchmann P

机构信息

First Department of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne and Dusseldorf, University of Cologne, Cologne, Germany; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.

First Department of Internal Medicine, Center for Integrated Oncology Aachen, Bonn, Cologne and Dusseldorf, University of Cologne, Cologne, Germany; German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.

出版信息

Ann Oncol. 2021 Jun;32(6):807-810. doi: 10.1016/j.annonc.2021.02.018. Epub 2021 Mar 3.

DOI:10.1016/j.annonc.2021.02.018
PMID:33667668
Abstract
摘要

相似文献

1
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study.PET-2 引导的强化 BEACOPP 方案治疗晚期结节性淋巴细胞为主型霍奇金淋巴瘤：德国霍奇金研究组 HD18 随机研究的亚组分析
Ann Oncol. 2021 Jun;32(6):807-810. doi: 10.1016/j.annonc.2021.02.018. Epub 2021 Mar 3.
2
PET2 -driven de-escalation therapy in 64 high-risk Hodgkin Lymphoma patients treated with escalated BEACOPP.采用PET2驱动的降阶梯疗法治疗64例接受强化BEACOPP方案治疗的高危霍奇金淋巴瘤患者。
Br J Haematol. 2015 Jul;170(2):278-81. doi: 10.1111/bjh.13287. Epub 2015 Jan 9.
3
Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.晚期霍奇金淋巴瘤患者接受四个周期的博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、泼尼松、丙卡巴肼（BEACOPP）强化方案，随后再接受四个周期的基线剂量BEACOPP方案的十年经验：一项单中心回顾性研究。
Leuk Lymphoma. 2015 Jul;56(7):2013-8. doi: 10.3109/10428194.2014.975804. Epub 2015 Feb 10.
4
Escalated BEACOPP in advanced Hodgkin's lymphoma.强化BEACOPP方案用于晚期霍奇金淋巴瘤。
Lancet. 2012 May 12;379(9828):1767-8. doi: 10.1016/S0140-6736(12)60153-6. Epub 2012 Apr 4.
5
Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone).BEACOPP 方案升级失败后的霍奇金淋巴瘤自体移植（博来霉素、依托泊苷、多柔比星、环磷酰胺、长春新碱、洛莫司汀和泼尼松）。
Leuk Lymphoma. 2013 Jan;54(1):36-40. doi: 10.3109/10428194.2012.702903. Epub 2012 Jul 9.
6
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14).早期预后不良霍奇金淋巴瘤患者的强化治疗：德国霍奇金研究组（GHSG HD14）随机、国际 3 期试验的长期随访结果
Lancet Haematol. 2021 Apr;8(4):e278-e288. doi: 10.1016/S2352-3026(21)00029-6.
7
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.PET 引导治疗晚期霍奇金淋巴瘤（HD18）：德国霍奇金研究组开展的一项开放标签、国际、随机 3 期临床试验的最终结果。
Lancet. 2017 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.
8
Sarcoidosis following escalated BEACOPP chemotherapy for stage IV Hodgkin lymphoma.IV期霍奇金淋巴瘤强化BEACOPP化疗后发生结节病。
Intern Med J. 2019 Apr;49(4):547-548. doi: 10.1111/imj.14246.
9
Modified escalated BEACOPP as salvage chemotherapy in classic Hodgkin lymphoma.改良强化BEACOPP方案作为经典型霍奇金淋巴瘤的挽救性化疗方案
Int J Hematol. 2010 Jul;92(1):211-3. doi: 10.1007/s12185-010-0630-9. Epub 2010 Jun 26.
10
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.与 4 个周期递增剂量 BEACOPP 序贯 4 个周期标准剂量 BEACOPP 联合或不联合放疗相比，8 个周期递增剂量 BEACOPP 治疗晚期霍奇金淋巴瘤患者：德国霍奇金研究组 HD12 试验的最终分析。
J Clin Oncol. 2011 Nov 10;29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Epub 2011 Oct 11.

引用本文的文献

1
Refining histopathological growth pattern-based risk group discrimination in nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.细化基于组织病理学生长模式的结节性淋巴细胞为主型霍奇金淋巴瘤风险组鉴别：来自德国霍奇金淋巴瘤研究组的分析
Leukemia. 2025 May 13. doi: 10.1038/s41375-025-02641-3.
2
Positron emission tomography-adapted therapy for first-line treatment in adults with Hodgkin lymphoma.正电子发射断层扫描适配疗法用于成人霍奇金淋巴瘤的一线治疗
Cochrane Database Syst Rev. 2025 Mar 26;3(3):CD010533. doi: 10.1002/14651858.CD010533.pub3.
3
PET Response and Outcome in Low-Risk Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Children's Oncology Group Study AHOD03P1.
低风险结节性淋巴细胞为主型霍奇金淋巴瘤的PET反应与预后：儿童肿瘤学组研究AHOD03P1
Pediatr Blood Cancer. 2025 May;72(5):e31606. doi: 10.1002/pbc.31606. Epub 2025 Feb 14.
4
Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early-stage Hodgkin's lymphoma.成人早期霍奇金淋巴瘤单纯化疗与化疗联合放疗的比较
Cochrane Database Syst Rev. 2024 Dec 2;12(12):CD007110. doi: 10.1002/14651858.CD007110.pub4.
5
Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?结节性淋巴细胞为主型霍奇金淋巴瘤的治疗：我们目前的状况如何？我们将何去何从？
Cancers (Basel). 2023 Jun 23;15(13):3310. doi: 10.3390/cancers15133310.
6
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.利妥昔单抗添加至一线化疗方案在结节性淋巴细胞为主型霍奇金淋巴瘤中的作用：意大利淋巴瘤基金会的一项研究
Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr.
7
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma.结节性淋巴细胞为主型霍奇金淋巴瘤的个体化患者护理。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):717-722. doi: 10.1182/hematology.2022000364.
8
Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up.利妥昔单抗含有的风险适应性治疗策略在结节性淋巴细胞为主型霍奇金淋巴瘤中的应用：7年随访
Cancers (Basel). 2021 Apr 7;13(8):1760. doi: 10.3390/cancers13081760.